Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, 44195, USA.
Nat Commun. 2019 Aug 2;10(1):3476. doi: 10.1038/s41467-019-10744-6.
Recent advances in DNA/RNA sequencing have made it possible to identify new targets rapidly and to repurpose approved drugs for treating heterogeneous diseases by the 'precise' targeting of individualized disease modules. In this study, we develop a Genome-wide Positioning Systems network (GPSnet) algorithm for drug repurposing by specifically targeting disease modules derived from individual patient's DNA and RNA sequencing profiles mapped to the human protein-protein interactome network. We investigate whole-exome sequencing and transcriptome profiles from ~5,000 patients across 15 cancer types from The Cancer Genome Atlas. We show that GPSnet-predicted disease modules can predict drug responses and prioritize new indications for 140 approved drugs. Importantly, we experimentally validate that an approved cardiac arrhythmia and heart failure drug, ouabain, shows potential antitumor activities in lung adenocarcinoma by uniquely targeting a HIF1α/LEO1-mediated cell metabolism pathway. In summary, GPSnet offers a network-based, in silico drug repurposing framework for more efficacious therapeutic selections.
近年来,DNA/RNA 测序技术的进步使得快速识别新靶点成为可能,并通过“精确”靶向个体化疾病模块,重新利用已批准的药物来治疗异质疾病。在这项研究中,我们开发了一种基于全基因组定位系统(GPSnet)的药物重定位算法,该算法通过专门针对从个体患者 DNA 和 RNA 测序图谱映射到人类蛋白质-蛋白质相互作用网络中得出的疾病模块来实现。我们研究了来自癌症基因组图谱中 15 种癌症类型的约 5000 名患者的全外显子组测序和转录组图谱。我们表明,GPSnet 预测的疾病模块可以预测药物反应,并为 140 种已批准的药物确定新的适应症。重要的是,我们通过实验验证了一种已批准的心脏心律失常和心力衰竭药物哇巴因通过独特地靶向 HIF1α/LEO1 介导的细胞代谢途径,在肺腺癌中具有潜在的抗肿瘤活性。总之,GPSnet 为更有效的治疗选择提供了一种基于网络的、计算机辅助的药物重定位框架。